FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048152631> ?p ?o ?g. }

• W3048152631 endingPage "1293" @default.
• W3048152631 startingPage "1293" @default.
• W3048152631 abstract "Dear Editor, We read with interest the correspondence “Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab”.1 To improve knowledge of this important topic, we would like to describe the experience of the Dermatology Unit of a reference university hospital located in Sassari, Italy. The COVID-19 epidemic has been causing a crisis of the national healthcare systems worldwide. The clinical management of patients has been significantly changed. The prescription of biologic therapies, which could favor SARS-CoV-2 infection and, then, the occurrence of a severe disease, has been a matter of debate.2 In Italy 214,103 cases of disease and 27,955 deaths were officially notified on May 7, 2020. Only a small proportion of patients were diagnosed in Sardinia (1,312 cases; 1,639,362 inhabitants). The psoriasis center of the University of Sassari, Sassari, Italy, followed up 1,140 patients, with 44.8% treated with systemic and biologic therapies or phototherapy. Overall, 125 (10.9%) patients, whose mean (range) age was 57 (20–82) years, were treated with TNF-α, Il-17, Il-12/23, and Il-23 inhibitors. The most prevalent comorbidities were diabetes, metabolic syndrome, obesity, cardiovascular disease, psoriatic arthritis, chronic renal failure, and IBD. Twenty-three patients with severe atopic dermatitis were administered dupilumab; their mean (range) age was 35 (20–52) years, and their most prevalent comorbidities were asthma and allergic rhinitis. Ten patients (mean age 38 years, range: 14–54 years) were treated with adalimumab for suppurative hidradenitis. Patients were followedup through telemedicine, but severe cases were admitted to ambulatories.3 Patients who started biologic therapies before the occurrence of the epidemic did not interrupt their therapy, as recommended by the American Academy of Dermatology, three completed the induction phase, and two severe psoriatic patients started the biologic therapy during the epidemic. Although the prevalence of comorbidities associated with severe COVID-19 is higher in the psoriatic population, 158 patients exposed to biologic therapies did not develop COVID-19. Patients exposed to systemic treatment (including the small-molecule apremilast) did not interrupt their medication course due to the infection. It is unclear if our cohort was exposed to SARS-CoV-2; however, our data are in line with those reported by other Italian dermatologic centers,4, 5 which highlighted the safety of biologic therapies. Furthermore, it can be hypothesized that the reduction of TNF-α and Il-17 can be associated with a less aggressive form of COVID-19.6 A multicenter study which could enroll a larger sample could help better understand the relationship between exposure to biologic therapies and SARS-CoV-2 and the role played by confounding factors (e.g., age, comorbidities, and other pharmacological therapies)." @default.
• W3048152631 created "2020-08-13" @default.
• W3048152631 creator A5000836360 @default.
• W3048152631 creator A5018470862 @default.
• W3048152631 creator A5041614587 @default.
• W3048152631 creator A5050411068 @default.
• W3048152631 creator A5071827015 @default.
• W3048152631 date "2020-08-06" @default.
• W3048152631 modified "2023-09-27" @default.
• W3048152631 title "Biologic drugs during COVID‐19 outbreak" @default.
• W3048152631 cites W3011555439 @default.
• W3048152631 cites W3016246315 @default.
• W3048152631 cites W3017244954 @default.
• W3048152631 cites W3020611303 @default.
• W3048152631 cites W3024184170 @default.
• W3048152631 cites W3036558320 @default.
• W3048152631 doi "https://doi.org/10.1111/ijd.15088" @default.
• W3048152631 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7436533" @default.
• W3048152631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32767379" @default.
• W3048152631 hasPublicationYear "2020" @default.
• W3048152631 type Work @default.
• W3048152631 sameAs 3048152631 @default.
• W3048152631 citedByCount "1" @default.
• W3048152631 countsByYear W30481526312021 @default.
• W3048152631 crossrefType "journal-article" @default.
• W3048152631 hasAuthorship W3048152631A5000836360 @default.
• W3048152631 hasAuthorship W3048152631A5018470862 @default.
• W3048152631 hasAuthorship W3048152631A5041614587 @default.
• W3048152631 hasAuthorship W3048152631A5050411068 @default.
• W3048152631 hasAuthorship W3048152631A5071827015 @default.
• W3048152631 hasBestOaLocation W30481526311 @default.
• W3048152631 hasConcept C126322002 @default.
• W3048152631 hasConcept C16005928 @default.
• W3048152631 hasConcept C187212893 @default.
• W3048152631 hasConcept C2776002364 @default.
• W3048152631 hasConcept C2776042228 @default.
• W3048152631 hasConcept C2776260265 @default.
• W3048152631 hasConcept C2778329239 @default.
• W3048152631 hasConcept C2779134260 @default.
• W3048152631 hasConcept C2779745271 @default.
• W3048152631 hasConcept C2779786854 @default.
• W3048152631 hasConcept C2780132546 @default.
• W3048152631 hasConcept C2780564577 @default.
• W3048152631 hasConcept C71924100 @default.
• W3048152631 hasConceptScore W3048152631C126322002 @default.
• W3048152631 hasConceptScore W3048152631C16005928 @default.
• W3048152631 hasConceptScore W3048152631C187212893 @default.
• W3048152631 hasConceptScore W3048152631C2776002364 @default.
• W3048152631 hasConceptScore W3048152631C2776042228 @default.
• W3048152631 hasConceptScore W3048152631C2776260265 @default.
• W3048152631 hasConceptScore W3048152631C2778329239 @default.
• W3048152631 hasConceptScore W3048152631C2779134260 @default.
• W3048152631 hasConceptScore W3048152631C2779745271 @default.
• W3048152631 hasConceptScore W3048152631C2779786854 @default.
• W3048152631 hasConceptScore W3048152631C2780132546 @default.
• W3048152631 hasConceptScore W3048152631C2780564577 @default.
• W3048152631 hasConceptScore W3048152631C71924100 @default.
• W3048152631 hasIssue "10" @default.
• W3048152631 hasLocation W30481526311 @default.
• W3048152631 hasLocation W30481526312 @default.
• W3048152631 hasOpenAccess W3048152631 @default.
• W3048152631 hasPrimaryLocation W30481526311 @default.
• W3048152631 hasRelatedWork W2195057011 @default.
• W3048152631 hasRelatedWork W2783970348 @default.
• W3048152631 hasRelatedWork W2904527393 @default.
• W3048152631 hasRelatedWork W2912355509 @default.
• W3048152631 hasRelatedWork W2920791236 @default.
• W3048152631 hasRelatedWork W3028355101 @default.
• W3048152631 hasRelatedWork W3106721720 @default.
• W3048152631 hasRelatedWork W3194750073 @default.
• W3048152631 hasRelatedWork W4313502673 @default.
• W3048152631 hasRelatedWork W4383186745 @default.
• W3048152631 hasVolume "59" @default.
• W3048152631 isParatext "false" @default.
• W3048152631 isRetracted "false" @default.
• W3048152631 magId "3048152631" @default.
• W3048152631 workType "article" @default.